- ETST
is in the process of trademarking and finalizing packaging for a medical
device designed to detect sexually transmitted infections
- The
biotech company is focused on developing medical devices for the
pharmaceutical and nutraceutical fields and marketing its high-grade line
of hemp cannabidiol (CBD)
- ETST
is bringing to market non-invasive medical devices and vaccines for women;
in vitro testing on the impact of its CBD formula on breast cancer cells
to begin in summer of 2019
Earth Science Tech, Inc. (OTC: ETST), through its Earth
Science Pharmaceutical subsidiary, is finalizing plans to launch global
marketing and sales of its MSN-2 home testing medical kit for the detection of
sexually transmitted infections (STI) in women. ETST plans to market it in such
far-flung countries as Vietnam and Morocco (http://ibn.fm/fILCz).
ETST, a biotech company based in Doral, Florida, has
repositioned its line of full spectrum CBD. As it conducts R&D for
non-invasive medical devices, it is also focused on manufacturing, marketing
and distributing its own cannabinoid products, including capsules and oils, to
the nutraceutical and pharmaceutical markets.
The company’s MSN-2 medical device is in its final stage
prior to the launch of large scale marketing. ETST is working with
Acceleration, Design et Innovation Inc. Final packaging is being designed to
appeal worldwide to its target audience of women. The device is developed to
detect chlamydia and other STIs. It is a home kit that collects human cells
which are then laboratory tested (http://ibn.fm/ATMSH).
In a news release, Dr. Michel Aube, CEO and chief science
officer of ETST, stated, “We will create a strong demand for this medical
device by showing the world its powerful capacity to diminish the prevalence of
chlamydia and other sexually transmitted infections.” He noted that ETST is in
the process of obtaining trademark protection for its logo and name.
In addition, funded by a grant from Quebec, Canada, ETST is
now prototyping three CBD patent formulas. In vitro testing will begin on the
first batch of formulas in the summer of 2019 to show the superior antioxidant
properties and anti-proliferative effects on breast cancer cells. The branding
of these products is in the planning stage.
ETST holds several wholly-owned subsidiaries. Cannabis
Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures
and distributes in the recreational sector. Earth Science Foundation, Inc. is
becoming a non-profit and accepts grants and donations to conduct additional
studies. Earth Science Pharmaceutical develops medical diagnostic tools and
vaccines. It also has subsidiary Canno Inno Laboratories Inc., a strategic
Montreal, Canada-based company formed to provide ETST with access to government
grants.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
